MGNX News and Press, MacroGenics Inc. From 09/16/21

21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A 78% of patients had tumor shrinkage at first scan Median duration of response was 10.3 months as of data cuto...

Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved partial responses (two confirmed and two unconfirmed) ...

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

A notable decliner on Wednesday, MacroGenics (NASDAQ: MGNX) stock came roaring back the next day to close almost 9% higher. The company has suffered a big setback, but there are obviously investors who still believe it has potential to make them money. The setback is that the co...

Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, ...

Today, we revisit MacroGenics for the first time in over a year. The company has one approved product on the market and continues to advance its pipeline. A full investment analysis is presented in the paragraphs below. For further details see: MacroGenics: Revisiting Ou...

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q2 2021 Earnings Call Jul 29, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q2 2021 Earnings Call Transcript

MacroGenics, Inc. (MGNX) Q2 2021 Earnings Conference Call July 29, 2021 4:30 PM ET Company Participants Chris James – Vice President of Investor Relations and Corporate Communications Scott Koenig – President and Chief Executive Officer Jim Karrels – Chief Financial Offic...

MacroGenics (NASDAQ:MGNX): Q2 GAAP EPS of -$0.66 misses by $0.08. Revenue of $30.8M (+52.0% Y/Y) misses by $1.35M.  Cash, cash equivalents and marketable securities as of June 30, 2021 were $297.3M, compared to $272.5M as of December 31, 2020. MacroGeni...